Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.
暂无分享,去创建一个
D. DeMets | D. Allred | R. Love | S. Mohsin | T. Havighurst | N. Duc | Qian Zhang | D. Craig Allred | Thomas C. Havighurst | Richard R. Love | D. DeMets | Nguyen Ba Duc | Syed K. Mohsin
[1] C. Osborne,et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.
[2] D. DeMets,et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] B. Rasmussen,et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Berry,et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Allred,et al. Testing for erbB-2 by immunohistochemistry in breast cancer. , 2000, American journal of clinical pathology.
[7] C. Osborne,et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[9] S. Bull,et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. Holmberg,et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[12] S. Martino,et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] R. Collins,et al. Ovarian ablation in early breast cancer: overview of the randomised trials , 1996, The Lancet.
[14] A. Bianco,et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Fernö,et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. , 1994, Cancer letters.
[16] B. Têtu,et al. Prognostic significance of HER‐2/neu oncoprotein expression in node‐positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy , 1994, Cancer.
[17] M. Gail,et al. Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.
[18] D. Cox. Regression Models and Life-Tables , 1972 .
[19] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[20] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .